Use of Lepirudin during Percutaneous Vascular Interventions in Patients with Heparin-Induced Thrombocytopenia

Journal of Invasive Cardiology

Volumn 15, Issue 11, 2003, Pages 617-621

  Cochran, Kevin ^b   DeMartini, Tony J ^b   Lewis, Bruce E ^a   O'Brien, James ^b   Steen, Lowell H ^b   Grassman, Eric D ^b   Leya, Ferdinand ^b  

^a Section of Cardiology   (United States)

^b NONE

Author keywords

Heparin; Hirudin; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LEPIRUDIN; MONOCLONAL ANTIBODY; PEPTIDE; RECOMBINANT HIRUDIN; RECOMBINANT PROTEIN; THROMBIN INHIBITOR; TIROFIBAN; TYROSINE;

ADULT; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; IATROGENIC DISEASE; MALE; METHODOLOGY; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROSPECTIVE STUDY; RETROPERITONEAL HEMORRHAGE; STROKE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TYROSINE;

EID: 0242577948     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan asgatroban) in patients with heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemostasis 1997;23:197-202.
2. Wallis DE, Lewis BE, Walenga JM. Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: A dinician's perspective. Semin Thromb Hemostasis 1999;25(Suppl):3-7.
3. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Applied Thrombosis/Hemostasis 1999;5(Suppl):S21-27.
4. Walls JT, Curtis JJ, Silver D, Boley TM. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990;108:686-693.
5. Izban KF, Lietz HW, Hoppensteadt DA, et al. Comparison of two PF4/ heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemostasis 1999;25(Suppl):51-56.
6. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851.
7. Lewis BE, Ferguson JJ, Grassman ED, et al. Successful coronary interventions performed with asgatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996;8:410-417.
8. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239.
9. Greinacher A, Poetzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haem 1994;71:247-251.
10. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexes with heparin or heparin bound endothelial cells. J Clin Invest 1994;93:81-88.
11. Blank M, Shoenfeld Y, Tavor S, et al. Antiplatelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Internat Immunol 2002;14:121-129.
12. Lewis BE, Grassman ED, Wrona L, Rangel Y. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coag Fibrinolysis 1997;8:54-58.
13. King DE, Kelton JG. Heparin-induced thrombocytopenia. Ann Intern Med 1984;100:535-540.
14. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
15. Liu JC, Lewis BE, Steen LH, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 2002;89:979-981.
16. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Organon (ORG 10172). Thromb Haemostasis 1993;70:554-561.
17. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
18. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides effective and sale anticoagulation in patients with heparin-induced thrombocytopenia type II: A prospective study. Circulation 1999;99:73-80.
19. Greinacher A, Volpel H, Janssens U, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593.
20. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue-plasminogen activator and intravenous steptokinase. Circulation 1987;76:142-154.
21. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: A randomized trial. Lancet 1999;353:429-438.
22. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000;356:2037-2044.
23. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing angioplasty. Circulation 1997;96:1445-1453.
24. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
25. Antman EM, et al. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
26. Peters RJG, Zao F, Lewis BS, et al., for the CURE Investigators. Aspirin dose and bleeding events in the CURE study. Eur Heart J 2002;4(Suppl):510.
27. Lincoff AM, Bittl, JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. The REPLACE-2 Randomized Trial. JAMA 2003;289:853-863.